Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer - Adventist HealthCare

Clinical Trial Details

JAVELIN OVARIAN 100

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Ovarian Cancer
Study Type: Interventional
Phase: Phase III
Study Start Date: 05/19/2016
Study Completion Date: 09/06/2019

This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy.

The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients.

NCT Number
NCT02718417
Principal Investigator(s)
Frederick Min, MD
Sponsor(s)
Pfizer
Participant Eligibility
  • Age: 18 - No Maximum
  • Gender: Female

Location

  • Shady Grove Adventist Aquilino Cancer Center
    9905 Medical Center Drive
    Rockville, MD 20850
    Main: 240-826-6297

Find a Doctor

Find an Adventist HealthCare affiliated doctor by calling our FREE physician referral service at 800-642-0101 or by searching our online physician directory.

View Doctors

Set Your Location

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.